Neuronal exosomes reveal Alzheimer's disease biomarkers in Down syndrome
2016 (English)In: Alzheimer's & Dementia, ISSN 1552-5260, E-ISSN 1552-5279, 1-9 p.Article in journal (Refereed) In press
INTRODUCTION: Individuals with Down syndrome (DS) exhibit Alzheimer's disease (AD) neuropathology and dementia early in life. Blood biomarkers of AD neuropathology would be valuable, as non-AD intellectual disabilities of DS and AD dementia overlap clinically. We hypothesized that elevations of amyloid-β (Aβ) peptides and phosphorylated-tau in neuronal exosomes may document preclinical AD.
METHODS: AD neuropathogenic proteins Aβ1-42, P-T181-tau, and P-S396-tau were quantified by enzyme-linked immunosorbent assays in extracts of neuronal exosomes purified from blood of individuals with DS and age-matched controls.
RESULTS: Neuronal exosome levels of Aβ1-42, P-T181-tau, and P-S396-tau were significantly elevated in individuals with DS compared with age-matched controls at all ages beginning in childhood. No significant gender differences were observed.
DISCUSSION: These early increases in Aβ1-42, P-T181-tau, and P-S396-tau in individuals with DS may provide a basis for early intervention as targeted treatments become available.
Place, publisher, year, edition, pages
2016. 1-9 p.
Alzheimer's disease, Amyloid-β, Blood biomarkers, Down syndrome, Hyperphosphorylated tau, Intellectual disability, Neuronal exosomes
Research subject Social Sciences, Psychology
IdentifiersURN: urn:nbn:se:lnu:diva-61278DOI: 10.1016/j.jalz.2016.08.012PubMedID: 27755974OAI: oai:DiVA.org:lnu-61278DiVA: diva2:1080741